Temodar is called Temodal in Europe.
Information about Temodar (Temozolomide)
Temodar (generic name: temozolomide) is an oral chemotherapy medication primarily used to treat certain types of brain cancer, including glioblastoma multiforme (GBM) and anaplastic astrocytoma. It is an alkylating agent that works by interfering with the cancer cell's ability to divide and grow, thus helping to reduce tumor size. Temodar is often used in combination with radiation therapy or other treatments, and it is known for its ability to cross the blood-brain barrier, which allows it to effectively treat brain tumors.
Product Highlights
- Temodar is commonly used for the treatment of newly diagnosed GBM, either alone or in combination with radiation therapy. It is also used to treat recurrent GBM after the initial treatment has been completed.
- It is indicated for patients with anaplastic astrocytoma, a type of malignant brain tumor that has a similar treatment protocol to glioblastoma.
- Temodar is occasionally used off-label for other types of brain cancer or tumors that are sensitive to chemotherapy.
Key Ingredient
Key Benefits
- Temodar is particularly effective against tumors in the brain due to its ability to cross the blood-brain barrier and directly target tumor cells.
- The oral capsule form allows patients to take the medication at home without the need for intravenous infusions, which can be less convenient and more invasive.
- When used as part of a treatment regimen for glioblastoma or anaplastic astrocytoma, Temodar has been shown to improve overall survival rates and progression-free survival.
- Compared to other chemotherapy treatments, Temodar is relatively well-tolerated and causes fewer side effects for many patients.
Direction of Use
- The dosage of Temodar depends on the specific condition being treated and the patient's overall health. For glioblastoma, the standard starting dose is typically 75 mg/m² of body surface area per day for 42 days, followed by a rest period. After the initial treatment phase, a higher dose of 150-200 mg/m² is given on the first day of a 28-day cycle for continued treatment.
- Temodar should be taken on an empty stomach, typically once daily before bedtime to reduce nausea. It should be swallowed whole with a glass of water and not be chewed or crushed. The capsules should be taken at the same time each day for consistency.
- Blood counts and liver function tests should be monitored regularly during treatment, as temozolomide can affect bone marrow and liver function.
- If a dose is missed, it should be taken as soon as possible unless it is almost time for the next dose. Do not take two doses at once.
Safety Concerns
- Temodar can cause myelosuppression, including low white blood cell counts (leukopenia), low red blood cell counts (anemia), and low platelet counts (thrombocytopenia), which can increase the risk of infections, bleeding, and fatigue. Regular blood tests are required to monitor blood counts.
- Nausea and vomiting are common side effects, especially early in treatment. Antiemetic medications may be prescribed to help manage these symptoms.
- Due to its effects on bone marrow, patients on Temodar may be at an increased risk of infections. Careful monitoring and immediate treatment for infections are necessary.
- Temodar may affect liver function, so liver enzyme tests should be conducted regularly.
- Temodar is contraindicated during pregnancy, as it can cause harm to the fetus. It is also not recommended during breastfeeding, as it may pass into breast milk.
- Long-term use of Temodar has been associated with an increased risk of developing secondary cancers, particularly in pediatric patients.
- Temodar can have neurotoxic effects, leading to symptoms such as confusion, seizures, or altered mental status in some patients.
Avoid Temodar (Temozolomide) If
- Temodar should be avoided during pregnancy as it can cause harm to the fetus. Women of childbearing age should use effective contraception while on treatment and for a period after stopping the medication.
- Temodar should not be used while breastfeeding, as it is unknown whether it passes into breast milk and could harm the infant.
- Temodar should be avoided in patients with severe liver impairment as it can worsen liver function and increase the risk of side effects.
- Patients with a history of severe myelosuppression or bone marrow disorders should avoid Temodar, as it may exacerbate these conditions.
- If you have had an allergic reaction to Temodar or any of its components, it should be avoided.
- Due to the risk of myelosuppression and infections, Temodar should not be used in patients with active or uncontrolled infections.
